A new Washington State University study suggests that people with obsessive-compulsive disorder, or OCD, outline that the severity of their symptoms used to be reduced by approximately half inside four hours of smoking hashish.
The researchers analysed data inputted into the Strainprint app by people who self-identified as having OCD, a condition characterised by intrusive, persistent thoughts and repetitive behaviours such as compulsively checking whether a door is locked. After smoking hashish, users with OCD reported it reduced their compulsions by 60%, intrusions, or unwanted thoughts, by 49% and anxiety by 52 per cent.
The study, recently published in the Publication of Affective Disorders, also found that higher doses and hashish with higher concentrations of CBD, or cannabidiol, were associated with larger reductions in compulsions.
“The results overall indicate that hashish may have some really useful short-term but not truly long-term effects on obsessive-compulsive disorder,” said Carrie Cuttler, the study’s corresponding writer and WSU assistant professor of psychology. “To me, the CBD findings are truly promising because it’s not intoxicating. This is an area of research that would truly get pleasure from clinical trials taking a look at changes in compulsions, intrusions and anxiety with pure CBD.”
The WSU study drew from data of more than 1,800 hashish sessions that 87 individuals logged into the Strainprint app over 31 months. The long time frame allowed the researchers to evaluate if users developed tolerance to hashish, but those effects were mixed. As people continued to use hashish, the associated reductions in intrusions became rather smaller suggesting they were building tolerance, but the relationship between hashish and reductions in compulsions and anxiety remained rather fixed.
Traditional treatments for obsessive-compulsive disorder include exposure and response prevention therapy where people’s irrational thoughts around their behaviours are directly challenged, and prescribing antidepressants called serotonin reuptake inhibitors to minimize symptoms. While these treatments have positive effects for lots of patients, they don’t cure the disorder nor do they work timely for each person with OCD.
“We’re trying to build knowledge approximately the relationship of hashish use and OCD because it’s an area that is truly understudied,” said Dakota Mauzay, a doctoral student in Cuttler’s lab and first writer on the paper.
Except their own research, the researchers found only one other human study on the topic: a small clinical trial with 12 participants that revealed that there have been reductions in OCD symptoms after hashish use, but these were not much larger than the reductions associated with the placebo.
The WSU researchers famous that one of the crucial limitations of their study used to be the inability to use a placebo keep watch over and an “expectancy effect” may play a role in the results, meaning when people expect to feel better from something they normally do. The data used to be also from a self-selected pattern of hashish users, and there used to be variability in the results because of this that not everyone experienced the same reductions in symptoms after the use of hashish.
On the other hand, Cuttler said this analysis of user-provided information via the Strainprint app used to be particularly valuable because it provides a large data set and the participants were the use of market hashish in their home surroundings, versus federally grown hashish in a lab which may impact their responses. Strainprint’s app is intended to help users resolve which types of hashish work the most efficient for them, but the company given the WSU researchers free access to users’ anonymized data for research purposes.
Cuttler said this study points out that further research, especially clinical trials on the hashish constituent CBD, may reveal a therapeutic potential for people with OCD.
This is the fourth study Cuttler and her colleagues have conducted examining the effects of hashish on quite a lot of mental health conditions the use of the data given by the app created by the Canadian company Strainprint. Others include studies on how hashish impacts PTSD symptoms, reduces headache pain and affects emotional well-being.
(This story has been published from a wire agency feed without modifications to the text.)
Follow more stories on Facebook and Twitter